A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State
Abstract
1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cancer Research UK. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence (accessed on 1 November 2022).
- Kazandjian, D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin. Oncol. 2016, 43, 676–681. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Risks and Causes of Myeloma, Cancer Research UK Website. Available online: https://www.cancerresearchuk.org/about-cancer/myeloma/risks-causes (accessed on 1 November 2022).
- Giordano. Multiple myeloma and pregnancy. (1st case in the world literature). Matern. Infanc. Arq. Med. Sociais 1965, 24, 158–184. [Google Scholar]
- Magen, H.; Simchen, M.J.; Erman, S.; Avigdor, A. Diagnosis and management of multiple myeloma during pregnancy: A case report, review of the literature, and an update on current treatments. Ther. Adv. Hematol. 2022, 13, 20406207211066173. [Google Scholar] [CrossRef]
- National Cancer Institute (NCI). Surveillance, Epidemiology and end Result (SEER) Programme. Available online: https//seer.cancer.gov/ (accessed on 1 November 2022).
- Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium, Royal College of Obstetricians and Gynaecologists Green-Top Guideline No. 37a, published April 2015. Available online: https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf (accessed on 1 November 2022).
- Lee, J.C.; Francis, R.S.; Smith, S.; Lee, R.; Bingham, C. Renal failure complicating myeloma in pregnancy. Nephrol. Dial. Transplant. 2007, 22, 3652–3655. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Khot, A.; Prince, H.M.; Harrison, S.J.; Seymour, J.F. Myeloma and pregnancy: Strange bedfellows? Leuk. Lymphoma 2014, 55, 966–968. [Google Scholar] [CrossRef]
- Brisou, G.; Bouafia-Sauvy, F.; Karlin, L.; Lebras, L.; Salles, G.; Coiffer, B.; Michallet, A.-S. Pregnancy and multiple myeloma are not amniotic. Leuk. Lymphoma 2013, 54, 2738–2741. [Google Scholar] [CrossRef] [PubMed]
- Oliver-Caldes, A.; Soler-Perromat, J.C.; Lozano, E.; Moreno, D.; Bataller, A.; Mozas, P.; Garrote, M.; Setoain, X.; Aróstegui, J.I.; Yagüe, J.; et al. Long term responders after autologous stem cell transplantation in multiple myeloma. Front. Oncol. 2022, 3151. [Google Scholar] [CrossRef]
- Bommert, K.; Bargou, R.C.; Stuhmer, T. Signalling and survival pathways in multiple myeloma. Eur. J. Cancer 2006, 42, 1574–1580. [Google Scholar] [CrossRef]
- Sahara, N.; Takeshita, A.; Ono, T.; Sugimoto, Y.; Kobayashi, M.; Shigeno, K.; Nakamura, S.; Shinjo, K.; Naito, K.; Shibata, K.; et al. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells. Exp. Hematol. 2006, 34, 736–744. [Google Scholar] [CrossRef]
- Matthes, T.; Manfroi, B.; Huard, B. Revisiting IL-6 antagonism in multiple myeloma. Crit. Rev. Oncol. Hematol. 2016, 105, 1–4. [Google Scholar] [CrossRef]
- Tavani, A.; Pregnolato, A.; La Vecchia, C.; Franceschi, S. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res. 1997, 21, 885–888. [Google Scholar] [CrossRef] [PubMed]
- Danel, L.; Vincent, C.; Rouseet, F.; Klein, B.; Bataille, R.; Flacher, M.; Durie, B.G.; Revillard, J.P. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J. Steroid Biochem. 1988, 30, 363–367. [Google Scholar] [CrossRef] [PubMed]
- Sola, B.; Renoir, J.-M. Estrogenic or antiestrogenic therapies for multiple myeloma? Molecular Cancer 2007, 59, 1–8. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ozerova, M.; Nefedova, Y. Estrogen promotes multiple myeloma through enhancing immunosuppressive activity of MDSC. Leuk. Lymphoma 2019, 60, 1557–1562. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, H.; Durie, B.G.; Bolejack, V.; Turesson, I.; Kyle, R.A.; Blade, J.; Fonseca, R.; Dimopoulos, M.; Shimizu, K.; Miguel, J.S.; et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysisof10 549 patients from the International Myeloma Working Group. Blood 2008, 111, 4039–4047. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Braun, T.; Challis, J.R.; Newnham, J.P.; Sloboda, D.M. Early-life glucocorticoid exposure: The hypothalamic-pituitaryadrenal axis, placental function, and long-term disease risk. Endocr. Rev. 2013, 34, 885–916. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Guller, S.; Kong, L.; Wozniak, R.; Lockwood, C.J. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: A potential role in preterm rupture of the fetal membranes. J. Clin. Endocrinol. Metab. 1995, 80, 2244–2250. [Google Scholar]
- Lockwood, C.J.; Radunovic, N.; Nastic, D.; Petkovic, S.; Aigner, S.; Berkowitz, G.S. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. J. Perinat. Med. 1996, 24, 243–251. [Google Scholar] [CrossRef]
- Park-Wyllie, L.; Mazzotta, P.; Pastuszak, A.; Moretti, M.E.; Beique, L.; Hunnisett, L.; Friesen, M.H.; Jacobson, S.; Kasapinovic, S.; Chang, S.; et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000, 62, 385–392. [Google Scholar] [CrossRef]
- Lergier, J.E.; Jiménez, E.; Maldonado, N.; Veray, F. Normal pregnancy in multiple myeloma treated with cyclophosphamide. Cancer 1974, 34, 1018–1022. [Google Scholar] [CrossRef]
- Durodola, J.I. Administration of cyclophosphamide during late pregnancy and early lactation: A case report. J. Natl. Med. Assoc. 1979, 71, 165–166. [Google Scholar]
- Jurczyszyn, A.; Olszewska-Szopa, M.; Vesole, A.S.; Vesole, D.H.; Siegel, D.S.; Richardson, P.G.; Paba-Prada, C.; Callander, N.S.; Huras, H.; Skotnicki, A.B. Multiple Myeloma in Pregnancy-A Review of the Literature and a Case Series. Clin. Lymphoma Myeloma Leuk. 2016, 16, 39–45. [Google Scholar] [CrossRef] [PubMed]
- Borja de Mozota, D.; Kadhel, P.; Dermeche, S.; Multigner, L.; Janky, E. Multiple myeloma and pregnancy: A case report and literature review. Arch. Gynecol. Obstet. 2011, 284, 945–950. [Google Scholar] [CrossRef] [PubMed]
- Malik, S.; Oliver, R.; Odejinmi, F. A rare association with hyperemesis: Pregnancy and multiple myeloma. J. Obstet. Gynecol. 2006, 26, 693–695. [Google Scholar] [CrossRef] [PubMed]
- McIntosh, J.; Lauer, J.; Gunatilake, R.; Knudtson, E. Multiple myeloma presenting as hypercalcemic pancreatitis during pregnancy. Obstet Gynecol. 2014, 124 (Suppl. S1), 461463. [Google Scholar] [CrossRef] [PubMed]
Reference | Relapse/Progression | Characteristic of Relapse | Treatment Given | Foetal Outcome | Maternal Outcome |
---|---|---|---|---|---|
J.C. Lee et al. [8] | Symtomatic relapse in postpartum period | Plasmacytosis in bone marrow, new bone lytic lesions, renal failure, hypercalcemia, and Paraprotein 41.1 g/L, | High-dose oral dexamethasone, four plasma exchanges, allopurinol, pamidronate, and renal dialysis. Vincristine, adriamycin, and dexamethasone chemotherapy planned. | Healthy | Deceased following intracerebral hemorrhage, 1 month after progression in postpartum period. |
Khot et al. [9] | Symtomatic progression during pregnancy | Rising serum free light chains, new bone marrow plasmacytosis of 20%, and anemia. | Lenalidomide and dexamethasone post cesarean-section. Plan to proceed to further high dose therapy and allogenic transplant at progression. | Healthy | Alive at 5 years since relapse when reported |
G. Brisou et al. [10] | Symtomaticrelapse during pregnancy | Back pain, rising kappa light chains, symptomatic anemia, new lytic lesions inskull, and pelvis on MRI. | Bortezomib, cyclophosphamide, and dexamethasone post-delivery. | Healthy | Alive at 19 months since relapse when last reported following second ASCT. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Elgabry, G.; Spencer, L.; Siddiqi, H.; Ojha, S.; Wandroo, F. A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State. Hematol. Rep. 2023, 15, 305-311. https://doi.org/10.3390/hematolrep15020031
Elgabry G, Spencer L, Siddiqi H, Ojha S, Wandroo F. A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State. Hematology Reports. 2023; 15(2):305-311. https://doi.org/10.3390/hematolrep15020031
Chicago/Turabian StyleElgabry, Gehad, Lydia Spencer, Hisam Siddiqi, Soumya Ojha, and Farooq Wandroo. 2023. "A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State" Hematology Reports 15, no. 2: 305-311. https://doi.org/10.3390/hematolrep15020031
APA StyleElgabry, G., Spencer, L., Siddiqi, H., Ojha, S., & Wandroo, F. (2023). A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State. Hematology Reports, 15(2), 305-311. https://doi.org/10.3390/hematolrep15020031